Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-01-12Actual
Enrollment · participants20Actual
Source updated2023-12-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.